

## **LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**CARBOARD BOX**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Porcilis APP Suspension for injection

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Each 2 ml dose contains:

*Actinobacillus pleuropneumoniae* antigen concentrate containing 50 units OMP [outer membrane protein], 50 units Apx I toxoid, 50 units Apx II toxoid and 50 units Apx III toxoid.

**3. PACKAGE SIZE**

20 ml (10 doses)  
50 ml (25 doses)  
100 ml (50 doses)  
250 ml (125 doses)

**4. TARGET SPECIES**

Pigs (weaned piglets)

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Intramuscular use.

**7. WITHDRAWAL PERIODS**

Withdrawal period: Zero days.

**8. EXPIRY DATE**

Exp {mm/yyyy}  
Once opened use within 10 hours.

**9. SPECIAL STORAGE PRECAUTIONS**

Store in a refrigerator.  
Do not freeze.  
Protect from light.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Intervet International B.V.

**14. MARKETING AUTHORISATION NUMBERS**

Vm 06376/5029

**15. BATCH NUMBER**

Lot {number}

**16. SPECIAL WARNING(S), IF NECESSARY**

**17. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: Read package leaflet.

**18. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

**POM-V** Veterinary medicinal product subject to prescription.

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

**PET/GLASS BOTTLE LABEL OF 100 ML AND, 250 ML**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Porcilis APP Suspension for injection

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Each 2 ml dose contains:

*Actinobacillus pleuropneumoniae* antigen concentrate containing 50 units of each of: OMP [outer membrane protein], and Apx I, Apx II and Apx III toxoids.

100 ml

250 ml

**3. TARGET SPECIES**

Pigs (weaned piglets)

**4. ROUTES OF ADMINISTRATION**

Intramuscular use.

Read the package leaflet before use.

**5. WITHDRAWAL PERIODS**

Withdrawal period: Zero days.

**6. EXPIRY DATE**

Exp {mm/yyyy}

Once opened use within 10 hours.

**7. SPECIAL STORAGE PRECAUTIONS**

Keep the bottle in the outer carton.

Store in a refrigerator.

Do not freeze.

Protect from light.

**8. NAME OF THE MARKETING AUTHORISATION HOLDER**

Intervet International B.V.

**9. BATCH NUMBER**

Lot {number}

**10. SPECIAL WARNING(S), IF NECESSARY**

**11. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: Read package leaflet.

**12. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF APPLICABLE**

For animal treatment only.

**POM-V** Veterinary medicinal product subject to prescription.

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**PET/GLASS BOTTLE LABEL OF 50 ML, 20 ML**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Porcilis APP



**2. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

Each 2 ml dose contains:

*Actinobacillus pleuropneumoniae* antigen concentrate containing 50 units of each of: OMP [outer membrane protein], and Apx I, Apx II and Apx III toxoids

20 ml

50 ml

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

Once opened use within 10 hours.

**5. ROUTE(S) OF ADMINISTRATION**

IM

**6. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

## **B. PACKAGE LEAFLET**



## PACKAGE LEAFLET

### 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Porcilis APP Suspension for injection for pigs

### 2. COMPOSITION

Each 2 ml dose contains:

#### Active substances:

*Actinobacillus pleuropneumoniae* antigen concentrate containing:

OMP [outer membrane protein]	50 units*
Apx I toxoid	50 units
Apx II toxoid	50 units
Apx III toxoid	50 units

\* units relative to an internal standard determined to be efficacious in pigs

#### Adjuvant:

dl- $\alpha$ -tocopherol (adjuvant)	150 mg
-------------------------------------	--------

#### Excipient:

Formaldehyde (preservative)	0.02 % w/v
-----------------------------	------------

Aqueous white suspension.

### 3. TARGET SPECIES

Pigs (weaned piglets).

### 4. INDICATIONS FOR USE

For the active immunisation of weaned piglets to reduce mortality, clinical signs and lesions of pleuropneumonia caused by *Actinobacillus pleuropneumoniae*.

Onset of immunity: 2 weeks after completion of the vaccination scheme.

Duration of immunity: 11 weeks after completion of the vaccination scheme.

### 5. CONTRAINDICATIONS

None.

### 6. SPECIAL WARNINGS

Special warnings for each target species:

Vaccinate healthy animals only.

Special precautions for use in animals:

It is not advisable to vaccinate animals immediately before and after feeding.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection or ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. If spilled on the skin, wash with soap and water.

Pregnancy and lactation:

Do not use during pregnancy or lactation.

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose:

No reactions other than those described in the “Adverse Events” section were observed following a double dose; however, the severity of clinical signs was increased.

Major incompatibilities:

Do not mix with any other veterinary medicinal product.

## 7. ADVERSE EVENTS

Pigs (weaned piglets):

Very common (>1 animal / 10 animals treated):	Injection site reaction <sup>1</sup> ; Anorexia, Decreased activity, Depression
Common (1 to 10 animals / 100 animals treated):	Elevated temperature <sup>2,3</sup> ; Decreased appetite <sup>3</sup> Increased respiratory rate <sup>3,4</sup> ; Vomiting <sup>3</sup>
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Anaphylaxis (severe allergic reaction)

<sup>1</sup> These are mild to moderate reactions, that resolve within 5 days post-vaccination.

<sup>2</sup> Increases up to 2 °C.

<sup>3</sup> Resolve within 24 hours after vaccination.

<sup>4</sup> With a change towards abdominal breathing and dyspnoea (difficulty breathing).

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder

using the contact details at the end of this leaflet, or via your national reporting system: e-mail: [adverse.events@vmd.gov.uk](mailto:adverse.events@vmd.gov.uk)  
<https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine> .

## **8. DOSAGE FOR EACH SPECIES, ROUTES AND METHOD OF ADMINISTRATION**

Dose: 2 ml.

Route of administration: Deep intramuscular injection.

Maximum protection should be achieved before the start of the fattening period.

Pigs may be vaccinated from 6 weeks of age.

Two doses at least 4 weeks apart are required. It is advised to give these at 6 and 10 weeks of age.

## **9. ADVICE ON CORRECT ADMINISTRATION**

Allow the vaccine to reach ambient temperature (between 15 °C to 25 °C) before use.

Shake bottle vigorously before and at intervals during use.

Clean and sterile vaccination equipment should be used.

The use of automatic vaccination equipment is recommended.

## **10. WITHDRAWAL PERIODS**

Zero days.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

Store in a refrigerator (2 °C – 8 °C).

Do not freeze.

Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label and carton after 'Exp'. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: 10 hours.

## **12. SPECIAL PRECAUTIONS FOR DISPOSAL**

Medicines should not be disposed of via wastewater.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. These measures should help to protect the environment.

Ask your veterinary surgeon how to dispose of medicines no longer required.

### 13. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

### 14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 06376/5029

Pack sizes: 20 ml (10 doses), 50 ml (25 doses), 100 ml (50 doses) or 250 ml (125 doses).

Not all pack sizes may be marketed.

### 15. **PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

### 16. CONTACT DETAILS

Marketing authorisation holder and contact details to report suspected adverse reactions:

Intervet International B.V.  
Wim de Körverstraat 35  
5831 AN Boxmeer  
Netherlands  
Tel.: +44 (0)1908 685685

Manufacturer responsible for batch release:

Intervet International B.V.  
Wim de Körverstraat 35  
5831 AN Boxmeer  
The Netherlands

### 17. OTHER INFORMATION

The active ingredients (Apx I, Apx II, Apx III and OMP) induce antibodies, which help to protect pigs against pleuropneumonia caused by *Actinobacillus pleuropneumoniae*.

The antigens are incorporated in an aqueous adjuvant in order to enhance stimulation of immunity.

For animal treatment only.

POM-V Veterinary medicinal product subject to veterinary prescription

Revised: February 2025  
AN: 03343/2024

Approved 04 February 2025

*Gavin Hall*